SignalFDA/Bio

Moderna and Merck's personalized mRNA vaccine cut death or recurrence by 42% vs standard treatment in a Phase 3 melanoma trial. 1,137 patients, stage IIB-IV, and they're already engaging regulators. T

Moderna and Merck report mRNA cancer vaccine cut death and recurrence by 42%.

Context

What happened: Merck and Moderna said a personalized mRNA vaccine against melanoma reduced the risk of death or recurrence by 42 percent versus standard treatment in a late-stage trial. Why it matters: Moderna CEO Stéphane Bancel said the results reinforce the companies' conviction that mRNA could fundamentally change how cancer is treated. The partners had reported the trial succeeded in August but held back details until the conference.

MRNA

$223.37

-3.45%

MRK

$147.76

+0.55%

What changed

Merck and Moderna said a personalized mRNA vaccine against melanoma reduced the risk of death or recurrence by 42 percent versus standard treatment in a late-stage trial.

Why it matters

Moderna CEO Stéphane Bancel said the results reinforce the companies' conviction that mRNA could fundamentally change how cancer is treated. The partners had reported the trial succeeded in August but held back details until the conference.

Sources